OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability

  • InteliSwab® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab® revenue
  • Signs a deal with Quest Diagnostics Genomic Sequencing Services for saliva collection kits
  • Q4 GAAP EPS of $0.21; Non-GAAP EPS of $0.36
  • Announces restructuring expected to result in operating expense savings of $15 million to be fully implemented by June 2023; targets achieving cash flow breakeven for core business by end of 2024
  • Cash balance grows to $111 million, up $9 million from prior quarter
  • Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET

BETHLEHEM, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended December 31, 2022.

“This quarter we have delivered clear progress on our transformation journey to Strengthen our foundation. We identified meaningful expense reductions through restructuring our two business units into a single organization, reducing our non-production workforce by 11%, and lowering manufacturing costs. Importantly, this quarter we further increased our cash balance that will help fund investments for our future,” said OraSure President and CEO Carrie Eglinton Manner.

She continued, “building from our stronger base, our focus this year is to increasingly Elevate core growth across our product lines by expanding our existing business, driving internal innovation, and targeting key strategic partnerships. We believe our actions will drive the Company to achieving cash flow breakeven for the core business by the end of 2024 while we Accelerate profitable growth.”

Financial Highlights

  Three Months Ended     Year Ended  
  December 31,     December 31,  
    2022       2021     % Change       2022       2021     % Change  
Core Diagnostics $ 18,400     $ 17,898     3   %   $ 70,007     $ 67,333     4   %
InteliSwab   88,857       14,770     502         233,666       22,707     929    
Total Diagnostics   107,257       32,668     228         303,673       90,040     237    
Core Molecular Solutions   15,684       22,936     (32 )       74,147       89,467     (17 )  
COVID-19 kits   137       7,964     (98 )       9,659       54,167     (82 )  
Total Molecular Solutions   15,821       30,900     (49 )       83,806       143,634     (42 )  
Total Revenue $ 123,078     $ 63,568     94   %   $ 387,479     $ 233,674     66   %
  Three Months Ended     Year ended  
  December 31,     December 31,  
    2022       2021     % Change         2022       2021     % Change    
Net revenues $ 123,078     $ 63,568     94   %   $ 387,479     $ 233,674     66   %
Gross profit   49,589       27,133     83         147,637       117,600     26    
Gross margin   40%       43%             38%       50%        
Non-GAAP gross profit   50,126       28,685     75         154,464       121,708     27    
Non-GAAP gross margin   41%       45%             40%       52%        
Operating income (loss)   13,435       (9,371 )   NM         (22,957 )     (10,164 )   NM    
Operating margin   11%       -15%             -6%       -4%        
Non-GAAP operating income (loss)   18,340       (1,336 )   NM         21,726       5,388     303    
Non-GAAP operating income (loss)   15%       -2%             6%       2%        
Net income (loss)   15,561       (10,393 )   NM         (17,935 )     (22,998 )   -22    
Non-GAAP net income (loss)   26,041       (2,490 )   NM         24,986       (7,847 )   (418 )  
GAAP EPS $ 0.21       ($0.14 )   NM         ($0.25 )     ($0.32 )   (23 )  
Non-GAAP EPS $ 0.36       ($0.03 )   NM   %     $0.34       ($0.11 )   (416 ) %

NM – not meaningful

  • Net revenues for the fourth quarter of 2022 were $123.1 million, a 94% increase from the fourth quarter of 2021 and a new record for the Company.
  • Total InteliSwab® test revenue of $88.9 million increased 12% sequentially as the Company continued to scale its production capacity and saw increased order volume supporting the Federal government’s school testing program.
  • Core Diagnostic revenue increased 3% versus the prior year primarily due to strong domestic growth in HIV and HCV product sales. The Company experienced delays of a large number of international diagnostic orders toward the end of the quarter due to timing of product availability which we believe will drive higher sales in the first quarter of 2023. Core Molecular Solutions revenue decreased 32% year-over-year predominantly due to lower order volumes at key customers. The Company believes that some of this decline is associated with customer destocking activity as many organizations focus on cash balances given challenging financial conditions.
  • GAAP gross margin percentage was 40.3% in the quarter compared to 42.7% in the fourth quarter of 2021. GAAP gross margins increased 60 basis points on a sequential basis. Non-GAAP gross margins in the quarter were 40.7% compared to 45.1% in the fourth quarter of 2021 and Non-GAAP gross margins increased 70 basis points on a sequential basis. On a year-over-year basis, gross margins were negatively impacted primarily by product mix, but improved sequentially with efficiencies achieved with the Company’s InteliSwab® test production.
  • GAAP operating income in the fourth quarter was $13.4 million which compares to a ($9.4) million operating loss in the fourth quarter of 2021 and increased $12.6 million on a sequential basis. Non-GAAP operating income was $18.3 million in the quarter compared to a ($1.3) million operating loss in the fourth quarter of 2021 and increased by $7.0 million on a sequential basis. This was driven by higher revenue, improved gross margins, and lower non-GAAP operating expenses which declined by $3.5 million sequentially due to timing and cost control.
  • Cash and short-term investments increased $9.2M sequentially to $110.8 million in Q4 2022. Working capital increased significantly in the fourth quarter, which the Company believes will convert to cash as InteliSwab® revenues begin to taper in the future.

Business Restructuring

The Company has shared a business restructuring combining its Molecular Solutions and Diagnostics business units into One OraSure. As part of the restructuring, the Company is announcing role eliminations that will affect 11% of its current non-production workforce. The Company believes that, when coupled with additional cost savings, these changes will lead to annualized operating expense reductions of approximately $15 million to be fully implemented by the end of the second quarter of 2023. With additional system changes and manufacturing site consolidation, the Company targets achieving cash flow breakeven on base business (excluding InteliSwab® revenue) by the end of calendar year 2024. The Company’s profitability turnaround enables current cash generation from InteliSwab® to be utilized for innovation and future growth investments.

“To support our long-term goals and growth as an organization, we’ve made the difficult decision to eliminate a number of roles,” said OraSure President and CEO Carrie Eglinton Manner. “The changes we made will streamline levels of leadership, centralize core enterprise functions, and prioritize value creation activities. We believe our new operating structure will unlock significant operating efficiencies, foster stronger collaboration across the organization, and allow us to increase our innovation pipeline for growth.”

Recent Business Highlights

  • Signed a deal with Quest Diagnostics to serve as the preferred provider of saliva collection kits for Quest’s Genomic Sequencing Services Group’s test offerings.
  • Received FDA approval for a new packaging and labeling configuration for InteliSwab®. The Company expects the new configuration to begin shipping by the end of March 2023. The packaging changes are expected to drive per test cost savings of approximately $0.40 which includes the impact from lower shipping costs based upon the smaller packaging configuration which should reduce total truckloads by approximately 50%.
  • Launched four new CE-IVD Collipee urine collection products to support growing interest in non-invasive HPV and STI screening diagnostics and liquid biopsy from first-void urine samples. Included among these launches is a product with a proprietary chemistry for cell-free DNA and extra-cellular vesicles for oncology applications.
  • Announced two new federal government contracts for InteliSwab®. The first procurement contract runs through November 2023; and, under the terms of the award, the contract estimate is 18 million InteliSwab® COVID-19 Rapid Tests, with a maximum award of 36 million tests and a guaranteed minimum award of 3.6 million tests. The second contract was awarded for 3.2 million tests in December of 2022.
  • Chosen as one of a group of manufacturers to win a Connecticut tender that allows the Company to compete for a total award of six million potential InteliSwab® tests annually.
  • Evaluating new respiratory applications to build upon our COVID-19 success, including internally and externally via strategic partnership.
  • Pursuing additional 510(k) clearances for the use of our proprietary collection kits in new applications in women’s health and oncology, similar to our recently announced co-clearance with Grifols.
  • Announced that its OraQuick HIV® Self-Test, in addition to its InteliSwab® test, is available for purchase directly via Amazon with eligibility for Prime free shipping.
  • Noted that the first microbiome based therapeutic received FDA approval which the Company views as a signal of positive catalyst for investment in the microbiome testing services industry.

Financial Guidance

The Company is guiding toward 1Q23 revenue of $125 to $130 million representing 85% to 92% growth relative to the first quarter of last year. Given the continued volatility with the COVID-19 market, OraSure is only providing quarterly financial guidance for fiscal year 2023; however, it is anticipating higher revenue in the first half of the year followed by lower sales in the second half as the Company works down its COVID-19 government contracts.

Financial Data (Unaudited)

    Three Months Ended   Year Ended
  December 31,   December 31,
      2022       2021       2022       2021  
Results of Operations                
Net revenues   $ 123,078     $ 63,568     $ 387,479     $ 233,674  
Cost of products and services sold     73,489       36,435       239,842       116,074  
Gross profit     49,589       27,133       147,637       117,600  
Operating expenses:                
Research and development     8,999       8,900       36,237       34,170  
Sales and marketing     11,363       10,915       49,238       44,751  
General and administrative     15,944       16,648       68,206       50,328  
Loss on impairment                 17,101        
Change in fair value of acquisition-related contingent consideration     (152 )     41       (188 )     (1,485 )
Total operating expenses     36,154       36,504       170,594       127,764  
Operating income (loss)     13,435       (9,371 )     (22,957 )     (10,164 )
Other income     1,960       443       6,480       872  
Income (loss) before income taxes     15,395       (8,928 )     (16,477 )     (9,292 )
Income tax expense (benefit)     (166 )     1,465       1,458       13,706  
Net income (loss)   $ 15,561     $ (10,393 )   $ (17,935 )   $ (22,998 )
Earnings (loss) per share:                
Basic   $ 0.21     $ (0.14 )   $ (0.25 )   $ (0.32 )
Diluted   $ 0.21     $ (0.14 )   $ (0.25 )   $ (0.32 )
Weighted average shares:                
Basic     72,734       72,040       72,505       71,981  
Diluted     73,248       72,040       72,505       71,981  
  Three Months Ended     Year Ended  
  December 31,     December 31,  
    2022     2021   %Change       2022     2021   %Change  
Infectious Disease Testing Revenues                          
Domestic HIV $ 4,126   $ 3,773   9   %   $ 16,241   $ 16,641   (2 ) %
International HIV   7,109     8,626   (18 )       22,571     25,503   (11 )  
Net HIV revenues   11,235     12,399   (9 )       38,812     42,144   (8 )  
Domestic HCV   1,913     1,301   47         8,353     6,881   21    
International HCV   1,274     1,100   16         5,016     4,902   2    
Net HCV revenues   3,187     2,401   33         13,369     11,783   13    
Net OraQuick® revenues   14,422     14,800   (3 )       52,181     53,927   (3 )  
COVID-19   88,857     14,770   502         233,666     22,707   929    
Other infectious disease revenues   127     183   (31 )       547     718   (24 )  
Total Infectious Disease   103,406     29,753   248         286,394     77,352   270    
Risk Assessment   2,483     2,406   3         10,269     9,678   6    
Other non-product revenues   1,368     509   169         7,010     3,010   133    
TOTAL DIAGNOSTIC NET REVENUE   107,257     32,668   228         303,673     90,040   237    
MOLECULAR SOLUTIONS                          
Genomics $ 9,777   $ 14,017   (30 )     $ 54,335   $ 63,350   (14 )  
Microbiome   1,920     2,050   (6 )       7,503     7,944   (6 )  
COVID-19   137     7,964   (98 )       9,659     54,167   (82 )  
Laboratory services   2,401     3,824   (37 )       7,296     11,840   (38 )  
Other product and services revenues   699     1,334   (48 )       2,591     2,566   1    
Net product and service revenues   14,934     29,189   (49 )       81,384     139,867   (42 )  
Other non-product and service revenues   887     1,711   (48 )       2,422     3,767   (36 )  
TOTAL MOLECULAR SOLUTIONS NET REVENUE   15,821     30,900   (49 )       83,806     143,634   (42 )  
TOTAL NET REVENUES $ 123,078   $ 63,568   94   %   $ 387,479   $ 233,674   66   %
Condensed Consolidated Balance Sheets (Unaudited)    
    December 31, 2022   December 31, 2021
Cash and cash equivalents   $ 83,980   $ 116,762
Short-term investments     26,867     36,279
Accounts receivable, net     70,797     45,323
Inventories     96,232     53,138
Other current assets     47,842     47,804
Property, plant and equipment, net     59,413     73,435
Intangible assets, net     11,694     14,343
Goodwill     35,104     40,279
Long-term investments         17,009
Other noncurrent assets     12,779     16,618
Total assets   $ 444,708   $ 460,990
Liabilities and Stockholders’ Equity        
Accounts payable   $ 39,349   $ 28,024
Deferred revenue     2,273     2,936
Other current liabilities     28,770     37,104
Other non-current liabilities     10,692     12,393
Stockholders’ equity     363,624     380,533
Total liabilities and stockholders’ equity   $ 444,708   $ 460,990
Additional Financial Data (Unaudited)   Year Ended
  December 31,
      2022       2021
Capital expenditures   $ 4,545     $ 48,117
Depreciation and amortization   $ 15,308     $ 11,658
Stock-based compensation   $ 11,622     $ 7,807
Cash used in operating activities   $ (47,202 )   $ 35,382

Conference Call

The Company will host a conference call and audio webcast for analysts and investors to discuss the Company’s fourth quarter 2022 results and certain business developments, beginning today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). On the call will be Carrie Eglinton Manner, President and Chief Executive Officer, Ken McGrath, Chief Financial Officer, and Scott Gleason, SVP Investor Relations and Corporate Communications. The call will include prepared remarks by management and a question and answer session.

In order to listen to the conference call, please register to obtain a dial in and pin at the following link:


To listen to the webcast, go to OraSure Technologies’ web site, www.orasure.com, and click on the Investor Relations page. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to the call. A replay of the call will be archived on OraSure Technologies’ web site shortly after the call has ended and will be available for 14 days. It is recommended to dial-in 15 to 20 minutes prior to the call start to reduce waiting times. If a participant will be listen-only, they are encouraged to listen via the webcast on OraSure’s Investor Relations page.

About InteliSwab®

OraSure has received Emergency Use Authorizations (EUA) from the FDA for its InteliSwab® COVID-19 rapid tests. The FDA has authorized the InteliSwab® COVID-19 Rapid Test for Over-the-Counter (OTC) use without a prescription. The FDA has also authorized the InteliSwab® COVID-19 Rapid Test Pro for professional use in point of care (POC) CLIA-waived settings, and the InteliSwab® COVID-19 Rapid Test Rx for Prescription Home Use. These remarkably simple COVID-19 lateral flow tests use samples self-collected from the lower nostrils. The InteliSwab® test’s unique design incorporates a built-in swab fully integrated into the test stick. After users swab their lower nostrils, the test stick is swirled in a pre-measured buffer solution, and the result appears right on the test stick within 30 minutes, with no instruments, batteries, smartphone or laboratory analysis needed to see the result. With less than one minute of “hands-on time,” it is as simple as “Swab, Swirl, and See.”

This product has not been FDA cleared or approved, but it has been authorized by the FDA under an EUA. The emergency use of this product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Multiple government agencies, including the U.S. Department of Defense (DoD) and Department of Health and Human Services (HHS) are working to address COVID-19 testing needs. Development of the InteliSwab® COVID-19 Rapid Test has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50120C00061 and 75A50121C00078, utilizing Health Care Enhancement Act (HCEA) funding. The DoD's Defense Assisted Acquisition (DA2) Cell led the manufacturing expansion effort for the InteliSwab® COVID-19 rapid test in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT). The manufacturing effort was funded through the American Rescue Plan Act (ARPA) to enable and support domestic industrial base expansion for critical medical resources.

About OraSure Technologies

OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

Forward Looking Statements

This press release contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations, revenue growth, cost savings, cash flow, increasing margins and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to reduce our spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of our business restructuring; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on the Company's business, supply chain, labor force, ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing, and demand for our COVID-19 testing products ; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks, civil unrest, hostilities and war ; and general political, business and economic conditions, including inflationary pressures. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

Statement Regarding Use of Non-GAAP Financial Measures

In this press release, the company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating income (loss), and non-GAAP earnings (loss) per share. Management believes that presentation of operating results using these non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company’s core operating results and comparison of operating results across reporting periods, while excluding certain expenses that may not be indicative of the Company’s recurring core business operating results. In addition, management believes these non-GAAP financial measures are useful to investors both because they (1) allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) are used by OraSure’s institutional investors and the analysis community to help them analyze the health of OraSure’s business. Management also uses non-GAAP financial measures to establish budgets and to manage the company’s business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of the schedules.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Further, non-GAAP financial measures, even if similarly titled, may not be calculated in the same manner by all companies, and therefore should not be compared.

  OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's)
    Three Months Ended   Year Ended
    December 31,   December 31,
      2022       2021       2022       2021  
  Revenue $ 123,078     $ 63,568     $ 387,479     $ 233,674  
  GAAP Cost of Goods Sold $ 73,489       36,435       239,842       116,074  
  GAAP Gross Margin   40%       43%       38%       50%  
  Stock compensation   140       162       331       572  
  Amortization of acquisition-related intangible assets   132       132       528       528  
  Transformation related expenses   265       -       1,599       -  
  Inventory reserve for excess levels   -       1,258       4,369       3,008  
  Non-GAAP Cost of Goods Sold   72,952       34,883       233,015       111,966  
  Non-GAAP Gross Margin   40.7%       45.1%       39.9%       52.1%  
  GAAP Operating Income (Loss)   13,435       (9,371 )     (22,957 )     (10,164 )
  Stock compensation   2,349       2,020       9,154       7,177  
  Amortization of acquisition-related intangible assets   467       707       1,937       2,843  
  Inventory reserve for excess levels   -       1,258       4,369       3,008  
  Loss on impairment   -       -       17,101       -  
  Transformation related expenses   520       1,200       6,191       1,200  
  Severance expense   300       2,683       3,850       2,683  
  Strategic alternative costs   -       126       848       126  
  Government grant accounting   1,422       -       1,422       -  
  Change in fair value of acquisition-related contingent consideration   (152 )     41       (188 )     (1,485 )
  Non-GAAP Operating Income (Loss)   18,340       (1,336 )     21,726       5,388  
  GAAP Net Income (Loss)   15,561       (10,393 )     (17,935 )     (22,998 )
  Stock compensation   2,349       2,020       9,154       7,177  
  Amortization of acquisition-related intangible assets   467       707       1,937       2,843  
  Inventory reserve for excess levels   -       1,258       4,369       3,008  
  Loss on impairment   -       -       17,101       -  
  Transformation related expenses   520       1,200       6,191       1,200  
  Severance expense   300       2,683       3,850       2,683  
  Strategic alternative costs   -       126       848       126  
  Change in fair value of acquisition-related contingent consideration   (152 )     41       (188 )     (1,485 )
  Tax effect of Non-GAAP adjustments   6,997       (132 )     (340 )     (401 )
  Non-GAAP Net Income (Loss) $ 26,041     $ (2,490 )   $ 24,986     $ (7,847 )
  GAAP Earnings (Loss) Per Share: $ 0.21     ($ 0.14 )   ($ 0.25 )   ($ 0.32 )
  Non-GAAP Earnings (Loss) Per Share: $ 0.36     ($ 0.03 )   $ 0.34     ($ 0.11 )
  Diluted Shares Outstanding   73,248       72,040       72,505       71,981  

Following is a description of the adjustments made to GAAP financial measures:

  • Stock Compensation: non-cash equity-based compensation provided to OraSure employees and directors, excluding accelerated stock compensation as required under former employees’ employment agreements
  • Amortization of acquisition-related intangible assets: represents recurring amortization charges resulting from the acquisition of intangible assets associated with our business combinations
  • Inventory reserve for excess levels: reserves recorded for inventory balances that are deemed excess based on current forecasts and expirations dates
  • Loss on impairment: charges related to the write down of company assets including PP&E and Goodwill
  • Transformation related expenses: transitory costs such as consulting and professional fees related to transformation initiatives
  • Strategic alternative costs: one-time expenses such as legal and banking fees tied to the company’s strategic alternative process
  • Severance expenses: Expenses tied to executive severance agreements including accelerated stock compensation
  • Government contract accounting: As required under International Accounting Standard Board IAS 20, Accounting for Government Contracts and Disclosure of Government Assistance, our operating expenses associated with the Department of Defense expansion contract are reflected in operating expenses with offsetting reimbursement reflected in other income
  • Change in fair value of acquisition-related contingent consideration: changes in the fair value of contingent consideration liability associated with estimate changes in reaching contingent consideration metrics
  • Tax impact associated with non-GAAP adjustments – tax expense/(benefit) due to non-GAAP adjustments
Investor Contact: Media Contact:
Scott Gleason Amy Koch
SVP Investor Relations & Corp. Communications Sr. Mgr. Corporate Communications
484-425-0588 484-523-1815
sgleason@orasure.com media@orasure.com

Primary Logo

Back to news